Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting two signaling points in the MAPK pathway.
Fourteen NRAS mutated...
Alternative Titles
Full title
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4320814
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4320814
Other Identifiers
ISSN
1476-4598
E-ISSN
1476-4598
DOI
10.1186/s12943-015-0293-5
